Failed Hepatitis C Drug Will Cost $1.8 Billion

Posted September 14, 2012
Only a week after the U.S. Centers for Disease Control and Prevention (CDC) advised all U.S. baby boomers to get tested for hepatitis C because it’s suspected that millions may be infected with it, a drug company with a hepatitis C treatment in the pipeline has suddenly abandoned the drug’s trials.  Bristol-Myers Squibb dropped the drug – called BMS-986094 – after one clinical trial patient died from heart failure and others were hospitalized with heart and kidney problems.  Read more.